Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin in Major Depressive Disorder
NCT03181529Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Aug 2017
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by Johns Hopkins University. Started Aug 2017; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03181529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181529.